{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:16:17Z","timestamp":1781532977645,"version":"3.54.5"},"reference-count":35,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>This systematic literature review evaluated the clinical efficacy and safety of interventions used in relapsed\/refractory follicular lymphoma. Primary efficacy outcomes were objective response rate, progression-free survival and overall survival. Safety endpoints were grade 3\/4 toxicities, serious adverse events and withdrawals or deaths due to toxicity. Studies were selected if they were randomized controlled trials reporting on the efficacy or safety of treatments for relapsed or refractory follicular lymphoma, and if outcomes were reported separately from trials that included other lymphoid neoplasms. We used the Bucher method for conducting adjusted indirect comparisons within a meta-analysis. We identified 10 randomized controlled trials of treatments for relapsed\/refractory follicular lymphoma. The most prominent drug investigated (alone or in combination) was rituximab. Most trials did not report median overall survival. Two trials reported median event-free survival (range, 1.2-23.2 months). Six of ten trials reported objective response rate (range, 9\u201393%). Meta-analysis showed only one statistically significant result: rituximab\u2009+\u2009bortezomib yielded a significantly higher objective response rate than rituximab monotherapy (relative risk, 1.28; 95% confidence interval, 1.11\u20131.47). Otherwise, there were no discernable differences in overall survival or progression-free survival, partly due to insufficient reporting of results in the clinical trials. The relatively small number of randomized controlled trials, few overlapping treatment arms, and variability in the randomized controlled trial features and in the endpoints studied complicate the formal comparison of therapies for relapsed\/refractory follicular lymphoma. Additional well-designed randomized controlled trials are needed to fully understand the relative outcomes of older and more recently developed therapies.<\/jats:p>","DOI":"10.1177\/1078155215603230","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T22:34:14Z","timestamp":1440801254000},"page":"666-678","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Randomized controlled trials in relapsed\/refractory follicular lymphoma: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"22","author":[{"given":"Rachel L","family":"Police","sequence":"first","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Trask","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Olivares","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"khan","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Abbe","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Colosia","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annete","family":"Njue","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Sherril","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Kaye","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milawukee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-1078155215603230","first-page":"590","volume":"36","author":"Fowler NH","year":"2011","journal-title":"P T"},{"key":"bibr2-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"bibr3-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1177\/107327481201900303"},{"key":"bibr4-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"bibr5-1078155215603230","unstructured":"National Institute for Health and Clinical Excellence. Single technology appraisal (STA). Specification for manufacturer\/sponsor submission of evidence, www.nice. org.uk\/media\/D6D\/E2\/SpecificationForManufacturerSponsorSubmissionEvidence.doc (2009, accessed 20 March 2013)."},{"key":"bibr6-1078155215603230","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care, www.york.ac.uk\/inst\/crd\/pdf\/Systematic_Reviews.pdf (accessed 20 March 2013)."},{"key":"bibr7-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"bibr8-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01850.x"},{"key":"bibr9-1078155215603230","first-page":"994","volume":"90","author":"Robak T","year":"2005","journal-title":"Haematologica"},{"key":"bibr10-1078155215603230","unstructured":"NCT00802737. Efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL), http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00802737?term=NCT00802737&rank=1 (accessed 2 July 2013)."},{"key":"bibr11-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.1191"},{"key":"bibr12-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"bibr13-1078155215603230","doi-asserted-by":"crossref","unstructured":"Coiffier B, Osmanov E, Hong X, et\u00a0al. Bortezomib-rituximab results in improved PFS and response rates versus rituximab, and quality of response is associated with improved outcomes, in patients with relapsed follicular lymphoma (FL). In:\n                      Presented at the 16th congress of the European hematology association\n                      , London, UK, 9\u201312 June 2011.","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"bibr14-1078155215603230","unstructured":"Rothman M, Pei L, Ganguly R, et\u00a0al. Patient-reported outcomes during and following treatment with bortezomib plus rituximab or rituximab alone in patients with relapsed follicular lymphoma (FL): results from a phase 3 study. In:\n                      Presented at the 16th congress of the European hematology association\n                      , London, UK, 9\u201312 June 2011."},{"key":"bibr15-1078155215603230","unstructured":"NCT00312845. Study of VELCADE and rituximab in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma, www.clinicaltrials.gov\/ct2\/show\/NCT00312845?term=NCT00312845&rank=1. (accessed 8 December 2013)."},{"key":"bibr16-1078155215603230","doi-asserted-by":"crossref","unstructured":"Coiffier B, Osmanov E, Hong X, et\u00a0al. A phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed, rituximab-naive or -sensitive, follicular lymphoma. In:\n                      Presented at the ASH Annual Meeting\n                      , Orlando, FL, 4\u20137 December 2010.","DOI":"10.1182\/blood.V116.21.857.857"},{"key":"bibr17-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"bibr18-1078155215603230","doi-asserted-by":"crossref","unstructured":"Leonard J, Jung S, Johnson J, et\u00a0al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. In:\n                      Presented at the 2012 ASCO annual meeting,\n                      Chicago, IL, 1\u20135 June 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.8000"},{"key":"bibr19-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"bibr20-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"bibr21-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"bibr22-1078155215603230","unstructured":"G\u00f3mez Almaguer D, Aung S, Kotb R, et\u00a0al. Inotuzumab ozogamicin plus rituximab versus defined investigator\u2019s choice in CD20+\/CD22+ follicular non-Hodgkin lymphoma. In:\n                      Presented at the 17th congress of the European hematology association\n                      , Amsterdam, Netherlands, 14\u201317 June 2012."},{"key":"bibr23-1078155215603230","unstructured":"NCT00268983. Comparison of rituximab versus tositumomab and iodine I 131 tositumomab (BEXXAR\u00ae therapeutic regimen) for patients with relapsed follicular non-Hodgkins lymphoma, www.clinicaltrials.gov\/ct2\/show\/NCT00268983?term=NCT00268983&rank=1. (accessed 8 December 2012.)."},{"key":"bibr24-1078155215603230","unstructured":"NCT00308087. Comparison study of rituximab plus sargramostim to rituximab alone for relapsed follicular B-cell lymphoma, a form of non-Hodgkin's lymphoma (PREMIER), www.clinicaltrials.gov\/ct2\/show\/NCT00308087?term=NCT00308087&rank=1. (accessed 8 December 2012)."},{"key":"bibr25-1078155215603230","unstructured":"NCT00400764. A study of dulanermin in combination with rituximab in subjects with follicular and other low grade, CD20+, non-Hodgkin's lymphomas, www.clinicaltrials.gov\/ct2\/show\/NCT00400764?term=NCT00400764&rank=1. (accessed 8 December 2012)."},{"key":"bibr26-1078155215603230","unstructured":"Goy A, Offner F, Martinelli G, et\u00a0al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. In:\n                      Presented at the 17th congress of the European hematology association\n                      , Amsterdam, Netherlands, 14\u201317 June 2012."},{"key":"bibr27-1078155215603230","doi-asserted-by":"crossref","unstructured":"Sehn LH, Goy A, Offner FC, et\u00a0al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. In:\n                      Presented at the ASH annual meeting\n                      , San Diego, CA, 10\u201313 December 2011.","DOI":"10.1182\/blood.V118.21.269.269"},{"key":"bibr28-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.417.3798521"},{"key":"bibr29-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu200"},{"key":"bibr30-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70311-0"},{"key":"bibr31-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"bibr32-1078155215603230","unstructured":"Zydelig (idelalisib) tablets [prescribing information]. Foster City, CA: Gilead Sciences, Inc., 2014."},{"key":"bibr33-1078155215603230","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084723"},{"key":"bibr34-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.0693"},{"key":"bibr35-1078155215603230","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215603230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215603230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215603230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:24Z","timestamp":1777688184000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215603230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1177\/1078155215603230"],"URL":"https:\/\/doi.org\/10.1177\/1078155215603230","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}